share_log

Redhill Biopharma | 424B5: Prospectus

Redhill Biopharma | 424B5: Prospectus

Redhill Biopharma | 424B5：募资说明书
SEC announcement ·  04/02 16:12
Moomoo AI 已提取核心信息
Redhill Biopharma Ltd. (Redhill), a specialty biopharmaceutical company, has announced the offering of 2,144,487 American Depositary Shares (ADSs) representing 857,794,800 ordinary shares, along with warrants to purchase up to an equivalent number of ADSs. The offering is detailed in a prospectus supplement filed pursuant to Rule 424(b)(5) under the Registration No. 333-258259. The combined purchase price for each ADS and accompanying warrant is $0.58289. The warrants, offered with the ADSs, are immediately exercisable at a price of $0.75 per ADS and will expire five years from the issuance date. Redhill has stated that there is no established public trading market for the warrants and does not expect one to develop. The ADSs issuable upon exercise of the warrants are also being offered by the prospectus...Show More
Redhill Biopharma Ltd. (Redhill), a specialty biopharmaceutical company, has announced the offering of 2,144,487 American Depositary Shares (ADSs) representing 857,794,800 ordinary shares, along with warrants to purchase up to an equivalent number of ADSs. The offering is detailed in a prospectus supplement filed pursuant to Rule 424(b)(5) under the Registration No. 333-258259. The combined purchase price for each ADS and accompanying warrant is $0.58289. The warrants, offered with the ADSs, are immediately exercisable at a price of $0.75 per ADS and will expire five years from the issuance date. Redhill has stated that there is no established public trading market for the warrants and does not expect one to develop. The ADSs issuable upon exercise of the warrants are also being offered by the prospectus supplement. The ADSs are listed on The Nasdaq Capital Market under the symbol 'RDHL.' The last reported sale price of the ADSs on Nasdaq was $0.5299 per ADS as of March 28, 2024. The company plans to use the net proceeds from the offering for working capital, acquisitions, and general corporate purposes. The date of the prospectus supplement is March 29, 2024.
专业生物制药公司红山生物制药有限公司（Redhill）宣布发行代表857,794,800股普通股的2,144,487股美国存托股票（ADS），以及购买最多等量ADS的认股权证。根据第424（b）（5）条在注册号333-258259下提交的招股说明书补充文件中详细介绍了此次发行。每份ADS和随附认股权证的总购买价格为0.58289美元。与ADS一起发行的认股权证可立即行使，价格为每份ADS0.75美元，并将自发行之日起五年内到期。Redhill表示，认股权证没有成熟的公开交易市场，预计不会发展。招股说明书补充文件也提供了行使认股权证后可发行的美国存托凭证。ADS在纳斯达克资本市场上市，股票代码为 “RDHL”。截至2024年3月28日，纳斯达克上次公布的ADS销售价格为每股ADS0.5299美元。该公司计划将此次发行的净收益用于营运资金、收购和一般公司用途。招股说明书补充材料的发布日期为2024年3月29日。
专业生物制药公司红山生物制药有限公司（Redhill）宣布发行代表857,794,800股普通股的2,144,487股美国存托股票（ADS），以及购买最多等量ADS的认股权证。根据第424（b）（5）条在注册号333-258259下提交的招股说明书补充文件中详细介绍了此次发行。每份ADS和随附认股权证的总购买价格为0.58289美元。与ADS一起发行的认股权证可立即行使，价格为每份ADS0.75美元，并将自发行之日起五年内到期。Redhill表示，认股权证没有成熟的公开交易市场，预计不会发展。招股说明书补充文件也提供了行使认股权证后可发行的美国存托凭证。ADS在纳斯达克资本市场上市，股票代码为 “RDHL”。截至2024年3月28日，纳斯达克上次公布的ADS销售价格为每股ADS0.5299美元。该公司计划将此次发行的净收益用于营运资金、收购和一般公司用途。招股说明书补充材料的发布日期为2024年3月29日。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息